The company will use the funds to commercialize a biomarker for colon cancer. Applied Proteomics’ system looks at activity patterns in the proteins encoded by a person’s genome rather than just the genome alone to detect early signs of cancer.
The $28 million contribution came from Genting Berhad, an investment holding company in Malaysia, as well as existing investors.
More Articles on Gastroenterology:
Vice & Associates Clinical Research Expands Gastroenterology Suite, Team Members
Drs. Rayees Nizam, Thomas Lee Join Associated Gastroenterologists of Central New York
5 Recent GI-Driven Center Openings & Plans
